Albany, NY -- (SBWIRE) -- 12/08/2016 -- GBI Research has released its latest report for the pharmaceuticals industry, "Type 2 Diabetes Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019". There is currently a large number of blood glucose-lowering drugs in the crowded type 2 diabetes market indicated for the treatment of chronically high blood glucose. The market is led by Lantus, which achieved global sales amounting to $6.4 billion in 2012. Over the forecast period from 2012 to 2019, the safer, more efficacious newer classes of drug (GLP-1 agonists, DPP-4 Inhibitors and SGLT-2 inhibitors) are expected to capture substantial market shares, largely replacing older classes such as sulfonylureas and thiazolidinediones. Additionally, a variety of novel drugs belonging to these newer classes are due to enter the market, and are expected to offer a moderate improvement in terms of efficacy and safety. The price of these new therapies is expected to be high, but this is unlikely to hinder their uptake. As a result, as well as an overall increase in the prevalent population, GBI Research believes that the value of the global market has the potential to grow to reach $38.8 billion by 2019.

View Report At: http://www.marketresearchreports.biz/analysis/175605

Scope

A brief introduction to type 2 diabetes, including the symptoms, pathogenesis, risk factors and diagnosis

In-depth analysis of major glucose-lowering drugs for type 2 diabetes, including analyses of their safety, efficacy, treatment patterns, strengths/weaknesses and overall commercial prospects. Includes a heat map comparing major drugs in terms of safety, efficacy and dosing parameters.

Comprehensive review of the pipeline for type 2 diabetes therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types and molecular targets.

Additional in-depth analysis of pipeline drug clinical trials by phase, molecule type, trial size, trial duration and program failure rate analyses for each molecule type and mechanism of action

Multi-scenario forecast data for the market up to 2019, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs, and changes in disease epidemiology across key developed markets including the US, Japan, Germany, the UK, France, Italy and Spain

Discussion of the drivers and barriers for market growth

Reasons to Buy

Understand the many different types of type 2 diabetes therapies on the market, from the older, established classes of treatment to newer, moderately superior types of drug, and their positions in the treatment algorithm

Understand the strengths and weaknesses of each product

Understand the scope of the pipeline, including which molecule types and mechanisms of action are prominent

Observe trends in clinical trial duration and size amongst clinical phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for type 2 diabetes therapeutics

Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the type 2 diabetes therapeutics market.

Download Sample copy of this Report at: http://www.marketresearchreports.biz/sample/sample/175605

Table of Contents

1 Table of Contents 1
1.1 List of Tables 5
1.2 List of Figures 6

2 Executive Summary 7
2.1 A Highly Competitive and Growing Market 7
2.2 Strong Pipeline Containing a Diverse Set of Products 8

3 Introduction 9
3.1 Epidemiology 9
3.2 Symptoms 9
3.3 Etiology 10
3.4 Pathophysiology 10
3.5 Co-morbidities and Complications 11
3.6 Classification 12
3.7 Prognosis 13
3.8 Diagnosis 13
3.9 Assessing Treatment Effectiveness 15
3.10 Treatment Algorithm 15
3.10.1 The Role of Insulin in Type 2 Diabetes 17
3.10.2 Non-insulin Diabetic Drugs 18
3.10.3 Other Drugs 20
3.11 GBI Research Report Guidance 20

4 Key Marketed Products 21
4.1 DPP-4 Inhibitors 21
4.1.1 Januvia (sitagliptin) – Merck & Co 21
4.1.2 Tradjenta (linagliptin) – Boehringer Ingelheim 23
4.1.3 Onglyza (saxagliptin) – Bristol-Myers Squibb and AstraZeneca 24
4.1.4 Nesina (alogliptin) – Takeda 24
4.1.5 Galvus (vildagliptin) – Novartis 25
4.2 GLP-1 Agonists 26
4.2.1 Byetta and Bydureon (exenatide) – Bristol-Myers Squibb 26
4.2.2 Lyxumia (lixisenatide) – Sanofi 27
4.2.3 Victoza (liraglutide) – Novo Nordisk 28
4.3 Sulfonylureas 28
4.3.1 Glimepiride 28
4.3.2 Gliclazide 29
4.4 Thiazolidinediones 30
4.4.1 Actos (pioglitazone) – Takeda Pharmaceuticals Limited 30
4.4.2 Avandia (rosiglitazone) – GlaxoSmithKline 31
4.5 Other 32
4.5.1 Metformin 32
4.5.2 Lantus (insulin glargine) – Sanofi 33
4.5.3 Levemir (insulin detemir) – Novo Nordisk 34
4.5.4 Forxiga (dapagliflozin) – Bristol-Myers Squibb 35
4.6 Heat Map for Marketed Products 35

5 Pipeline for Type 2 Diabetes 39
5.1 Overall Pipeline 39
5.2 Therapeutic Classes 40
5.3 Rate of Attrition 42
5.3.1 Failure Rate by Molecule Type 42
5.3.2 Failure Rate by Therapeutic Class 44

About MarketResearchReports.biz
MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
Website: http://www.marketresearchreports.biz/
E: sales@marketresearchreports.biz